GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Cyclically Adjusted Book per Share

Astellas Pharma (Astellas Pharma) Cyclically Adjusted Book per Share : $5.25 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Astellas Pharma's adjusted book value per share for the three months ended in Dec. 2023 was $5.823. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.25 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Astellas Pharma's average Cyclically Adjusted Book Growth Rate was 6.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 6.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Astellas Pharma was 6.40% per year. The lowest was 4.00% per year. And the median was 4.95% per year.

As of today (2024-04-27), Astellas Pharma's current stock price is $9.55. Astellas Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $5.25. Astellas Pharma's Cyclically Adjusted PB Ratio of today is 1.82.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Astellas Pharma was 3.62. The lowest was 1.95. And the median was 2.91.


Astellas Pharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Astellas Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Cyclically Adjusted Book per Share Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.07 5.34 5.53 5.28 5.31

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.26 5.31 4.97 4.90 5.25

Competitive Comparison of Astellas Pharma's Cyclically Adjusted Book per Share

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PB Ratio falls into.



Astellas Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=5.823/106.8000*106.8000
=5.823

Current CPI (Dec. 2023) = 106.8000.

Astellas Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201403 5.555 95.700 6.199
201406 5.462 98.000 5.952
201409 5.465 98.500 5.926
201412 5.220 97.900 5.695
201503 4.991 97.900 5.445
201506 5.002 98.400 5.429
201509 5.110 98.500 5.541
201512 5.044 98.100 5.491
201603 5.247 97.900 5.724
201606 5.494 98.100 5.981
201609 5.862 98.000 6.388
201612 5.505 98.400 5.975
201703 5.454 98.100 5.938
201706 6.009 98.500 6.515
201709 6.005 98.800 6.491
201712 6.000 99.400 6.447
201803 6.048 99.200 6.511
201806 5.910 99.200 6.363
201809 5.953 99.900 6.364
201812 5.992 99.700 6.419
201903 6.004 99.700 6.432
201906 6.128 99.800 6.558
201909 6.387 100.100 6.815
201912 6.467 100.500 6.872
202003 6.446 100.300 6.864
202006 6.539 99.900 6.991
202009 6.779 99.900 7.247
202012 7.099 99.300 7.635
202103 6.882 99.900 7.357
202106 6.778 99.500 7.275
202109 6.945 100.100 7.410
202112 6.951 100.100 7.416
202203 6.740 101.100 7.120
202206 6.288 101.800 6.597
202209 6.301 103.100 6.527
202212 6.371 104.100 6.536
202303 6.279 104.400 6.423
202306 6.215 105.200 6.310
202309 6.171 106.200 6.206
202312 5.823 106.800 5.823

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Astellas Pharma  (OTCPK:ALPMY) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Astellas Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=9.55/5.25
=1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Astellas Pharma was 3.62. The lowest was 1.95. And the median was 2.91.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Astellas Pharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (Astellas Pharma) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (Astellas Pharma) Headlines

From GuruFocus